Better Dividend Stock: AbbVie or Johnson & Johnson?

There are many dividend stocks on the market, but few are as prominent as (NYSE: ABBV) and Johnson Johnson (NYSE: JNJ). These companies have raised their payouts for over 50 consecutive years, making them members of the small club of Dividend Kings. Though AbbVie and Johnson Johnson are both great for passive income, these corporations have important differences. Investors on a budget may want to pick just one of these two options, but which one looks like the better Dividend stock?

At first glance, AbbVie doesn't seem like a particularly attractive stock right now. The company's revenue is dropping. Last year, it lost patent protection for what was by far its biggest cash cow -- and one of the most lucrative drugs in the industry's history -- immunology medicine Humira. Even so, AbbVie expects to return to top-line growth in 2025. Its roster of newer medicines is picking up the slack.

That's particularly the case with Skyrizi and Rinvoq, which round out the drugmaker's immunology lineup. Together, these medicines will generate $27 billion in revenue by 2027, roughly $6 billion more than Humira's peak sales. Their sales will continue growing long after. AbbVie's lineup boasts several other blockbusters, and the company's innovative wheel is still spinning.

Continue reading

Source Fool.com